CompletedPhase 2

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

South Korea84 participantsStarted 2019-04-09

Plain-language summary

The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.

Who can participate

Age range40 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. General Subject Inclusion Criteria
✓. Cognitively normal individuals
✓. Subjects with Mild Cognitive Impairment
✓. Subjects with Alzheimer Disease

Exclusion criteria

✕. General Exclusion Criteria
✕. Cognitively normal individuals
✕. Subjects with Mild Cognitive Impairment
✕. Subjects with Alzheimer Disease

What they're measuring

Cross-sectional PI-2620 uptake measured by standard uptake value ratio (SUVR)

Timeframe: 60-90 minutes post injection

Trial details

NCT IDNCT03903211

SponsorJae Seung Kim

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-28

View on ClinicalTrials.gov More Cognitively Normal trials